Olarif- DS

Olopatadine USP 0.2%

Sterile and Pyrogen Free Eye Drops

Composition

• Olarif DS Sterile and Pyrogen free Eye Drops: Each ml contains Olopatadine Hydrochloride USP equivalent to Olopatadine 2 mg.

Description

• It is a sterile and pyrogen-free ophthalmic solution containing Olopatadine Hydrochloride, a relatively selective H1 -receptor antagonist and mast cell stabilizer for topical administration to the eyes.

Clinical Pharmacology

Olopatadine inhibits the release of histamine from the mast cell and is a relatively selective histamine H1 -antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine-induced effects on human conjunctival epithelial cells. Olopatadine has no effects on alpha-adrenergic, dopamine, and muscarinic type 1 and 2 receptors. Olopatadine was shown to have low systemic exposure after topical administration.

Indications and Usage

These eye drops are indicated for the treatment of signs and symptoms (itchy, watery, red, and swollen eyes and/or eyelids) of allergic conjunctivitis including vernal keratoconjunctivitis, vernal keratitis, blepharitis, blepharoconjunctivitis and giant papillary conjunctivitis.

Dosage and Administration

• The recommended dose is 1 drop in the affected eye(s) two times daily.

Contraindications

• It is contraindicated in persons with a known hypersensitivity to any component of this product.

Precautions

Patients should be advised not to wear a contact lens if their eye is red. Olopatadine ophthalmic solution should not be used to treat contact lens-related irritation. Benzalkonium Chloride, the preservative of this drop, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least 10 minutes after installation of these eye drops before they insert their contact lenses. The treatment should be discontinued in the presence of an allergic reaction.

Side Effects

Rarely headaches have been reported. Other adverse effects: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, and taste perversion.

Use in Pregnancy & Lactation

Olopatadine was found not to be teratogenic in rats and rabbits. There are, however, no adequate and well-controlled studies in pregnant women. This drug should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus.

It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities of human breast milk. Nevertheless, caution should be exercised when olopatadine is administered to a nursing mother.

Overdosage

There is no information on Olopatadine overdose. However, excessive use of any medication can have serious consequences. If you suspect an overdose, seek medical attention without delay.

Storage

Store in a cool and dry place, and protect from light. Do not use longer than one month after first opening. Keep out of the reach of children.

Commercial Pack

• Olarif DS sterile Eye Drops: Each plastic dropper bottle contains 5 ml sterile eye drops.

Biopharma Ltd. Produces OLARIF DS EYE DROPS it is a trusted product for alleviating various discomforts, and it's commonly found in pharmacies and stores.